| Year |
Citation |
Score |
| 2020 |
Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer. PMID 32896505 DOI: 10.1016/J.Clgc.2020.08.004 |
0.366 |
|
| 2020 |
Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Mouw KW, Taplin ME, et al. Genomic predictors of good outcome, recurrence or progression in High grade T1 non-muscle invasive bladder cancer. Cancer Research. PMID 32868381 DOI: 10.1158/0008-5472.Can-20-0977 |
0.366 |
|
| 2020 |
Dee EC, Mahal BA, Arega MA, D'Amico AV, Mouw KW, Nguyen PL, Muralidhar V. Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. Jama Oncology. PMID 32789489 DOI: 10.1001/Jamaoncol.2020.3545 |
0.334 |
|
| 2020 |
Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V. Three-tiered sub-classification system of high-risk prostate cancer in men managed with radical prostatectomy: Implications for treatment decision-making. Urology. PMID 32763323 DOI: 10.1016/J.Urology.2020.07.040 |
0.337 |
|
| 2020 |
Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Choueiri TK, Trinh QD, Nguyen PL, Orio PF. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology. PMID 32654951 DOI: 10.1016/J.Urolonc.2020.05.023 |
0.368 |
|
| 2020 |
Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors. International Journal of Radiation Oncology, Biology, Physics. PMID 32585335 DOI: 10.1016/J.Ijrobp.2020.06.024 |
0.33 |
|
| 2020 |
Koyen AE, Madden MZ, Park D, Minten EV, Kapoor-Vazirani P, Werner E, Pfister NT, Haji-Seyed-Javadi R, Zhang H, Xu J, Deng N, Duong DM, Pecen TJ, Frazier Z, Nagel ZD, ... ... Mouw KW, et al. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene. PMID 32457468 DOI: 10.1038/S41388-020-1332-2 |
0.328 |
|
| 2020 |
de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, ... Mouw KW, et al. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology. PMID 32205136 DOI: 10.1016/J.Euo.2020.02.010 |
0.317 |
|
| 2020 |
Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW. ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer. Cancer Research. PMID 32127357 DOI: 10.1158/0008-5472.Can-19-3126 |
0.396 |
|
| 2020 |
Butler SS, Dee EC, Lamba N, Sha ST, Mahal BA, Whitbeck A, Makkar R, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V. Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. PMID 32073662 DOI: 10.1002/Cncr.32778 |
0.34 |
|
| 2020 |
Dee EC, King MT, Butler S, Yu Z, Sha S, Yang DD, Mahal BAV, Mouw KW, D'Amico AV, Nguyen PL, Muralidhar V. Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer. Journal of Clinical Oncology. 38: 135-135. DOI: 10.1200/Jco.2020.38.6_Suppl.135 |
0.365 |
|
| 2020 |
Yang DD, Butler S, Muralidhar V, Mahal BAV, Martin NE, Mouw KW, Nguyen PL, King MT, Orio PF. Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer. Journal of Clinical Oncology. 38: 101-101. DOI: 10.1200/Jco.2020.38.6_Suppl.101 |
0.351 |
|
| 2020 |
Choudhury AD, Xie W, Parikh M, Lee D, Kessler ER, Einstein DJ, Kochupurakkal B, Mouw KW, Van Allen EM, Doyle LA, D'Andrea AD, Taplin M, Shapiro G. A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 38: TPS5597-TPS5597. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps5597 |
0.358 |
|
| 2020 |
Dee* E, King M, Butler S, Yu Z, Sha S, Yang D, Mahal B, Mouw K, DʼAmico A, Nguyen P, Muralidhar V. MP53-10 SURGICAL MANAGEMENT VERSUS COMBINATION RADIOTHERAPY IN GLEASON SCORE 9-10 PROSTATE CANCER The Journal of Urology. 203: e786. DOI: 10.1097/Ju.0000000000000915.010 |
0.353 |
|
| 2019 |
Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H, Kochupurakkal B, D'Andrea AD, Shapiro GI, Lazaro JB, Mouw KW. Functional profiling of nucleotide Excision repair in breast cancer. Dna Repair. 82: 102697. PMID 31499327 DOI: 10.1016/J.Dnarep.2019.102697 |
0.315 |
|
| 2019 |
Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 941-948. PMID 31390585 DOI: 10.6004/Jnccn.2018.7283 |
0.328 |
|
| 2019 |
Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31271825 DOI: 10.1016/J.Ijrobp.2019.06.2510 |
0.357 |
|
| 2019 |
Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. PMID 31150125 DOI: 10.1002/Cncr.32202 |
0.344 |
|
| 2019 |
Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, et al. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. The New England Journal of Medicine. 380: 2070-2072. PMID 31116925 DOI: 10.1056/Nejmc1900333 |
0.346 |
|
| 2019 |
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright JL, Dall'Era M, Douglas J, Boormans JL, van der Heijden MS, Wu CL, van Rhijn BW, ... ... Mouw KW, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30952638 DOI: 10.1158/1078-0432.Ccr-18-3558 |
0.34 |
|
| 2019 |
Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. The Oncologist. PMID 30755500 DOI: 10.1634/Theoncologist.2018-0794 |
0.308 |
|
| 2019 |
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. European Urology. PMID 30712971 DOI: 10.1016/J.Eururo.2019.01.011 |
0.327 |
|
| 2019 |
King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. PMID 30638912 DOI: 10.1016/J.Brachy.2018.12.007 |
0.319 |
|
| 2019 |
Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. European Urology. 75: 35-41. PMID 30554605 DOI: 10.1016/J.Eururo.2018.08.033 |
0.349 |
|
| 2019 |
Nassar A, Mouw KW, Esplin ED, Yang S, Callis T, Nuzzo PV, Chanza NM, Choueiri TK, Kwiatkowski DJ, Sonpavde G. Germline alterations in urothelial carcinoma (UC) patients with family history of UC. Journal of Clinical Oncology. 37: 474-474. DOI: 10.1200/Jco.2019.37.7_Suppl.474 |
0.301 |
|
| 2019 |
Nassar A, Mouw KW, Curran C, Agarwal A, Acosta A, Preston MA, Mossanen M, Ravi A, Hirsch MS, Choueiri TK, Kwiatkowski DJ, Sonpavde G. Genomic profiling of variant urinary tract tumor histologies. Journal of Clinical Oncology. 37: 450-450. DOI: 10.1200/Jco.2019.37.7_Suppl.450 |
0.319 |
|
| 2019 |
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo M, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, et al. Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Sy05-03 |
0.393 |
|
| 2019 |
Kubler K, Karlic R, Haradhvala NJ, Ha K, Kim J, Kuzman M, Jiao W, Gakkhar S, Mouw KW, Braunstein LZ, Elemento O, Biankin AV, Rooman I, Miller M, Nogiec CD, et al. Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin Cancer Research. 79: 2727-2727. DOI: 10.1158/1538-7445.Am2019-2727 |
0.385 |
|
| 2019 |
Costa JBD, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall’Era MA, Douglas J, Boormans L, Heijden MSVD, Wu C, Rhijn BWGV, ... ... Mouw KW, et al. Molecular characterization of neuroendocrine-like bladder cancer European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30464-6 |
0.318 |
|
| 2019 |
Yang D, Butler S, Muralidhar V, Mahal B, Martin N, Mouw K, Nguyen P, King M, Orio P. Impact of Prostate-Directed Radiation Therapy on Overall Survival for Patients with M1a Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 105: E315-E316. DOI: 10.1016/J.Ijrobp.2019.06.1787 |
0.349 |
|
| 2018 |
Nassar AH, Umeton R, Kim J, Lundgren K, Harshman LC, Van Allen EM, Preston MA, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30593515 DOI: 10.1158/1078-0432.Ccr-18-3147 |
0.309 |
|
| 2018 |
Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. The Lancet. Oncology. 19: e683-e695. PMID 30507435 DOI: 10.1016/S1470-2045(18)30693-4 |
0.35 |
|
| 2018 |
Brody Y, Kimmerling RJ, Maruvka YE, Benjamin D, Elacqua JJ, Haradhvala NJ, Kim J, Mouw KW, Frangaj K, Koren A, Getz G, Manalis SR, Blainey PC. Quantification of somatic mutation flow across individual cell division events by lineage sequencing. Genome Research. PMID 30459213 DOI: 10.1101/Gr.238543.118 |
0.332 |
|
| 2018 |
Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, ... ... Mouw K, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. The Journal of Clinical Investigation. PMID 30179225 DOI: 10.1172/Jci121924 |
0.368 |
|
| 2018 |
Mouw KW. Towards biomarker-informed trimodality therapy (TMT) approaches for muscle-invasive bladder cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 30103024 DOI: 10.1016/J.Ijrobp.2018.07.2020 |
0.308 |
|
| 2018 |
Li Q, Damish A, Frazier ZJ, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, ... ... Mouw KW, et al. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29980530 DOI: 10.1158/1078-0432.Ccr-18-1001 |
0.392 |
|
| 2018 |
Haradhvala NJ, Kim J, Maruvka YE, Polak P, Rosebrock D, Livitz D, Hess JM, Leshchiner I, Kamburov A, Mouw KW, Lawrence MS, Getz G. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nature Communications. 9: 1746. PMID 29717118 DOI: 10.1038/S41467-018-04002-4 |
0.353 |
|
| 2018 |
Mouw KW, D'Andrea AD. DNA Repair Deficiency and Immunotherapy Response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018782425. PMID 29683789 DOI: 10.1200/Jco.2018.78.2425 |
0.31 |
|
| 2018 |
Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. European Urology. PMID 29478736 DOI: 10.1200/Jco.2018.36.6_Suppl.59 |
0.331 |
|
| 2018 |
Yang DD, Muralidhar V, Mahal BAV, Vastola M, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Orio PF, Choueiri TK, Trinh Q, Nguyen PL. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Journal of Clinical Oncology. 36: 78-78. DOI: 10.1200/Jco.2018.36.6_Suppl.78 |
0.353 |
|
| 2018 |
Miyamoto DT, Gibb E, Mouw KW, Liu Y, Wu C, Drumm M, Lehrer J, Ashab HA, Erho N, Du Plessis M, Ong K, Shipley WU, Davicioni E, Efstathiou JA. Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy. Journal of Clinical Oncology. 36: 513-513. DOI: 10.1200/Jco.2018.36.6_Suppl.513 |
0.35 |
|
| 2018 |
Nassar A, Lundgren K, Pomerantz M, Van Allen EM, Choudhury AD, Harshman LC, Preston MA, Mouw KW, Wei XX, McGregor BA, Choueiri TK, Bellmunt J, Kwiatkowski DJ, Sonpavde G. FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians. Journal of Clinical Oncology. 36: 465-465. DOI: 10.1200/Jco.2018.36.6_Suppl.465 |
0.315 |
|
| 2018 |
Miyamoto D, Gibb E, Mouw K, Liu Y, Wu C, Drumm M, Lehrer J, Ashab H, Erho N, Du Plessis M, Ong K, Shipley W, Davicioni E, Efstathiou J. OC-0049: Genomic profiling of muscle invasive bladder cancer to predict response to chemoradiation therapy Radiotherapy and Oncology. 127: S21. DOI: 10.1016/S0167-8140(18)30359-1 |
0.322 |
|
| 2018 |
Fitzpatrick K, Hwang J, Cai M, Liu D, Kochupurakkal B, Van Allen E, DAndrea A, Mouw K. Preclinical Models of DNA Repair Deficiency in Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e156. DOI: 10.1016/J.Ijrobp.2018.07.607 |
0.385 |
|
| 2018 |
Yang D, Mahal B, Muralidhar V, Martin N, King M, Mouw K, Nguyen P, Orio P. Whole-Pelvic Versus Prostate-Only Radiation Therapy in Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Androgen Deprivation Therapy and Brachytherapy Boost International Journal of Radiation Oncology*Biology*Physics. 102: e150-e151. DOI: 10.1016/J.Ijrobp.2018.07.293 |
0.344 |
|
| 2017 |
King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urologic Oncology. PMID 29276060 DOI: 10.1016/J.Urolonc.2017.11.022 |
0.366 |
|
| 2017 |
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications. 8: 2193. PMID 29259186 DOI: 10.1038/S41467-017-02320-7 |
0.371 |
|
| 2017 |
Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clinical Genitourinary Cancer. PMID 29196209 DOI: 10.1016/J.Clgc.2017.10.013 |
0.357 |
|
| 2017 |
Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 99: 904-911. PMID 29063853 DOI: 10.1016/J.Ijrobp.2017.07.034 |
0.37 |
|
| 2017 |
Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nature Biotechnology. PMID 28892075 DOI: 10.1038/Nbt.3966 |
0.317 |
|
| 2017 |
Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF, King MT, Nguyen PL. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. PMID 28832984 DOI: 10.1002/Cncr.30948 |
0.365 |
|
| 2017 |
Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nature Genetics. PMID 28825726 DOI: 10.1038/Ng.3934 |
0.334 |
|
| 2017 |
Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery. PMID 28630051 DOI: 10.1158/2159-8290.Cd-17-0226 |
0.347 |
|
| 2017 |
Mouw KW. DNA Repair Pathway Alterations in Bladder Cancer. Cancers. 9. PMID 28346378 DOI: 10.3390/Cancers9040028 |
0.41 |
|
| 2017 |
Efstathiou JA, Gibb E, Miyamoto DT, Wu C, Drumm M, Lehrer J, Ashab HA, Erho N, du Plessis M, Ong K, Bhat A, Mouw KW, Davicioni E, Shipley WU. Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy. Journal of Clinical Oncology. 35: 287-287. DOI: 10.1200/Jco.2017.35.6_Suppl.287 |
0.34 |
|
| 2017 |
Tripathi A, Friderici J, Preston MA, Trinh Q, Mouw K, Beard C, Bellmunt J, Stewart JA, Kibel AS, Harshman LC. Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis. Journal of Clinical Oncology. 35: e16001-e16001. DOI: 10.1200/Jco.2017.35.15_Suppl.E16001 |
0.306 |
|
| 2017 |
Liu D, Abbosh P, Keliher D, Reardon B, Mouw KW, Taylor-Weiner A, Mullane SA, Han G, Teo M, Kim J, Al-Ahmadie H, Iyer G, Dulaimi E, Chen D, Hoffman-Censits JH, et al. Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer. Journal of Clinical Oncology. 35: 4512-4512. DOI: 10.1200/Jco.2017.35.15_Suppl.4512 |
0.349 |
|
| 2017 |
Mouw K, Lazaro J, Damish A, Reznichenko E, Frazier Z, Liu D, Kim J, Polak P, Garraway L, Getz G, Rosenberg J, Allen EV, D'Andrea A. Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-Pr18 |
0.411 |
|
| 2017 |
Maruvka YE, Mouw KW, Karlic R, Parasuraman R, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Braunstein LZ, D’Andrea A, Lawrence MS, Bass A, Bernards A, et al. Abstract LB-280: The landscape of somatic microsatellite indels across cancer: detection and identification of driver events Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-280 |
0.315 |
|
| 2017 |
Liu D, Keliher D, Abbosh P, Mouw K, Miao D, Boyd M, Hoffman-Censits J, Iyer G, Tolaney S, Kim J, Getz G, Carter S, Bellmunt J, Plimack ER, Rosenberg JE, et al. Abstract 2918: Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature Cancer Research. 77: 2918-2918. DOI: 10.1158/1538-7445.Am2017-2918 |
0.363 |
|
| 2017 |
Efstathiou J, Gibb E, Miyamoto D, Wu C, Drumm M, Lehrer J, Ashab H, Erho N, du Plessis M, Ong K, Bhat A, Mouw K, Davicioni E, Shipley W. Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality Therapy International Journal of Radiation Oncology*Biology*Physics. 99: S118. DOI: 10.1016/J.Ijrobp.2017.06.278 |
0.319 |
|
| 2017 |
Frazier Z, Damish A, Reznichenko E, Liu D, Rosenberg J, Van Allen E, Lazaro J, D'Andrea A, Mouw K. Mapping the Functional Landscape of ERCC2 Mutations in Muscle-Invasive Bladder Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S32-S33. DOI: 10.1016/J.Ijrobp.2017.06.089 |
0.332 |
|
| 2016 |
Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, et al. Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852700 DOI: 10.1158/1078-0432.Ccr-16-2017 |
0.308 |
|
| 2016 |
Mouw K, Braunstein LZ, Kim J, Polak P, Getz G, D'Andrea AD. Somatic ERCC2 Mutations Are Associated With a Distinct Mutational Signature in Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S54. PMID 27675955 DOI: 10.1016/J.Ijrobp.2016.06.141 |
0.351 |
|
| 2016 |
Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Tiao G, Kwiatkowski DJ, Rosenberg JE, Van Allen EM, D'Andrea AD, Getz G. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nature Genetics. PMID 27111033 DOI: 10.1038/Ng.3557 |
0.379 |
|
| 2016 |
Pike JW, Mouw KW, Braunstein LZ, Martin NE, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Genomic features of primary and recurrent anal squamous cell carcinoma. Journal of Clinical Oncology. 34: 556-556. DOI: 10.1200/Jco.2016.34.4_Suppl.556 |
0.383 |
|
| 2016 |
Liu D, Abbosh P, Miao D, Boyd ME, Hoffman-Censits JH, Iyer G, Tolaney SM, Mouw KW, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM. Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy. Journal of Clinical Oncology. 34: 4518-4518. DOI: 10.1200/Jco.2016.34.15_Suppl.4518 |
0.335 |
|
| 2015 |
Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Research. 75: 628-34. PMID 25634215 DOI: 10.1158/0008-5472.Can-14-2593 |
0.404 |
|
| 2015 |
Ceccaldi R, O'Connor K, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. Abstract POSTER-BIOL-1331: Nucleotide excision repair mutations confer sensitivity to platinum but not PARP-inhibitors in epithelial ovarian cancer Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1331 |
0.418 |
|
| 2014 |
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623 |
0.376 |
|
| 2014 |
Mouw KW, D'Andrea AD. Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. Dna Repair. 19: 130-4. PMID 24768451 DOI: 10.1016/J.Dnarep.2014.03.019 |
0.343 |
|
| 2014 |
Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, et al. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Journal of Clinical Oncology. 32: 4510-4510. DOI: 10.1200/Jco.2014.32.15_Suppl.4510 |
0.391 |
|
| 2014 |
Mouw K, Van Allen E, O’Connor K, Wagle N, Kim P, Al-Ahmadie H, Zhu C, Ostravnaya I, Iyer G, Signoretti S, Reuter V, Getz G, Kantoff P, Bochner B, Choueiri T, et al. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S88. DOI: 10.1016/J.Ijrobp.2014.05.481 |
0.356 |
|
| 2013 |
Keenholtz RA, Mouw KW, Boocock MR, Li NS, Piccirilli JA, Rice PA. Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavage. The Journal of Biological Chemistry. 288: 29206-14. PMID 23970547 DOI: 10.1074/Jbc.M113.508028 |
0.641 |
|
| 2013 |
Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Seminars in Radiation Oncology. 23: 109-14. PMID 23473687 DOI: 10.1016/J.Semradonc.2012.11.009 |
0.348 |
|
| 2012 |
Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EE, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncology. 48: 1025-30. PMID 22621836 DOI: 10.1016/J.Oraloncology.2012.04.004 |
0.303 |
|
| 2010 |
Mouw KW, Steiner AM, Ghirlando R, Li NS, Rowland SJ, Boocock MR, Stark WM, Piccirilli JA, Rice PA. Sin resolvase catalytic activity and oligomerization state are tightly coupled. Journal of Molecular Biology. 404: 16-33. PMID 20868695 DOI: 10.1016/J.Jmb.2010.08.057 |
0.583 |
|
| 2010 |
Rice PA, Mouw KW, Montaño SP, Boocock MR, Rowland SJ, Stark WM. Orchestrating serine resolvases. Biochemical Society Transactions. 38: 384-7. PMID 20298188 DOI: 10.1042/Bst0380384 |
0.546 |
|
| 2009 |
Rowland SJ, Boocock MR, McPherson AL, Mouw KW, Rice PA, Stark WM. Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. Molecular Microbiology. 74: 282-98. PMID 19508283 DOI: 10.1111/J.1365-2958.2009.06756.X |
0.577 |
|
| 2008 |
Mouw KW, Rowland SJ, Gajjar MM, Boocock MR, Stark WM, Rice PA. Architecture of a serine recombinase-DNA regulatory complex. Molecular Cell. 30: 145-55. PMID 18439894 DOI: 10.1016/J.Molcel.2008.02.023 |
0.546 |
|
| 2007 |
Mouw KW, Rice PA. Shaping the Borrelia burgdorferi genome: crystal structure and binding properties of the DNA-bending protein Hbb. Molecular Microbiology. 63: 1319-30. PMID 17244195 DOI: 10.1111/J.1365-2958.2007.05586.X |
0.554 |
|
| Show low-probability matches. |